🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Affiliated Hospital of Jiangnan University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Affiliated Hospital of Jiangnan University as lead sponsor. Synced 26 Sep 2026
6Current trials
2Recruiting now
1Drug in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Affiliated Hospital of Jiangnan University is the lead sponsor of 6 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase EARLY_PHASE1. The drugs named most often in its trials are 18F-FDG. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

  • Recruiting233%
  • By invitation467%

Trials by phase

  • Phase EARLY_PHASE1350%
  • Not applicable350%
01

Clinical trials sponsored by Affiliated Hospital of Jiangnan University

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors
NCT06684028 · ClinicalTrials.gov ↗ · Cancer, Solid Malignancies
Not applicable Recruiting 2023-07 China
Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
NCT07798778 · ClinicalTrials.gov ↗ · Metastatic Castration-Resistant Prostate Cancer
Phase EARLY_PHASE1 Recruiting 2026-07 China
PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors
NCT07023848 · ClinicalTrials.gov ↗ · Breast Cancer, Gastric Cancer (GC), Urothelial Carcinoma (UC)
Drug: 18F-FDG
Phase EARLY_PHASE1 By invitation 2025-07 China
The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
NCT06723665 · ClinicalTrials.gov ↗ · Prostate Cancer
Drug: 18F-FDG
Not applicable By invitation 2024-01 China
Evaluation of [68Ga]DOTA-IR-780-C-4 in PET Imaging Studies for PSMA-Positive Prostate Cancer Patients
NCT07162779 · ClinicalTrials.gov ↗ · PET CT
Not applicable By invitation 2024-10 China
The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
NCT07023861 · ClinicalTrials.gov ↗ · Breast Cancer, Gastric Cancer (GC), Urothelial Carcinoma (UC)
Drug: 18F-FDG
Phase EARLY_PHASE1 By invitation 2025-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Affiliated Hospital of Jiangnan University trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Affiliated Hospital of Jiangnan University trials

8 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China62

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Breast Cancer

SponsorTrials
Fudan University48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University21
Second Affiliated Hospital, Zhejiang University, School of Medicine19
AstraZeneca15
Shengjing Hospital15
Pfizer12
Sichuan Baili Pharmaceutical12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences12
Hoffmann-La Roche10
Ruijin Hospital10

Sponsors with the most current trials registered for this condition.

06

Questions about Affiliated Hospital of Jiangnan University trials

How many clinical trials does Affiliated Hospital of Jiangnan University sponsor?

Affiliated Hospital of Jiangnan University is the lead sponsor of 6 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Affiliated Hospital of Jiangnan University trials recruiting?

Yes. 2 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Affiliated Hospital of Jiangnan University testing?

Its current trials name 1 drug or biological as interventions. The most frequent are 18F-FDG (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.